MicroPort CardioFlow Medtech Corporation announced that the Company successfully registered VitaFlow LibertyTM transcatheter aortic valve implantation system (th "VitaFlow Liberty ") in Argentina. VitaFlow Liberty is second-generation transcatheter aortic heart valve implantation ("TAVI") product, and the second product that registered in Argentina after first-generation TAVI product VitaFlow . VitaFlow LibertyTM has received its registration approval from the National Medical Products Administration of the People's Republic of China on August 30, 2021 and completed the registration application of CE Mark (certification mark that indicates conformity with health, safety
and environmental protection standards for products sold within the European Economic Area) on December 28, 2021. Please refer to the announcements of the Company dated August 31, 2021 and December 28, 2021 for details.
Compared to first-generation TAVI product, the key upgrade of VitaFlow LibertyTM lies in the unique and innovative double helix structure of its delivery system, that guarantees retrieval of the PAV (prosthetic aortic valve) and provides optimized pass performance, which helps to pass the anatomical abnormalities. It is equipped with the only commercialized motorized handle worldwide, enabling deployment and retrieval of the PAV are conducted in a stable, accurate and fast manner. It is currently the only delivery system in China that can allow the valve segment to achieve 360-degree bending. first-generation tip-preshaped super stiff guidewire Angelguide was also registered together with VitaFlow LibertyTM in Argentina. The tip-preshaped super stiff guidewire features high guidewire rail support and smooth transition in order to reduce the risks of vascular damage and enhance the accuracy of deployment. In addition, VitaFlow Liberty introduces the innovative design of integrated catheter sheath, making it suitable for patients with different blood vessel characteristics. That the registration of VitaFlow LibertyTM in Argentina marks another solid step forward for international roadmap, and will immediately embark on the promotion of VitaFlow Liberty in Argentina to benefit local patients with heart valve disease.